INCB000928

Phase 2Small molecule

INCB000928 is one of 84 small molecule programs targeting Fibrodysplasia Ossificans Progressiva. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fibrodysplasia Ossificans ProgressivaActive, not recruiting

Myelodysplastic SyndromesActive, not recruiting

Myeloproliferative DisorderActive, not recruiting

Fibrodysplasia Ossificans ProgressivaPhase 2

Active, not recruiting

Myelodysplastic SyndromesPhase 1/Phase 2

Active, not recruiting

Myeloproliferative DisorderPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

207 competitors in Myelodysplastic Syndromes

#DrugCompanyPhaseTrials

Reblozyl

Bristol-Myers Squibb

Phase 3

15 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

8 3

Promacta

GSK

Phase 3

2 4

Thalomid

Bristol-Myers Squibb

Phase 3

2 5

Fludara

Sanofi

Phase 3

2 6

Xospata

Astellas

Phase 3

1 7

Rydapt

Novartis

Phase 3

1 8

Neupogen

EEastern Cooperative Oncology Group

Phase 3

4 9

Zarnestra

KKura Oncology, Inc.

Phase 3

4 10

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Active, not recruiting

Myeloproliferative Disorder

NCT04455841

Q1 2033

Phase 2Recruiting

Fibrodysplasia Ossificans Progressiva

NCT05090891

Clinical

Trials by Indication[1]

Myeloproliferative Disorder1 trial

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

Active, not recruiting· Incyte logo

Incyte·Phase 1/2·NCT04455841·84 enrolled

Fibrodysplasia Ossificans Progressiva1 trial

To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

Recruiting· Incyte logo

Incyte·Phase 2·NCT05090891·98 enrolled

Myelodysplastic Syndromes1 trial

To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma

Terminated· Incyte logo

Incyte·Phase 1/2·NCT04582539·22 enrolled

Impaired Renal Function1 trial

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

Completed· Incyte logo

Incyte·Phase 1·NCT05099445·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for INCB000928. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INCB000928 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INCB000928. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Incyte company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Incyte

INCB000928

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2033

Trials by Indication[1]

Myeloproliferative Disorder1 trial

Fibrodysplasia Ossificans Progressiva1 trial

Myelodysplastic Syndromes1 trial

Impaired Renal Function1 trial

References

Drug Info

Quick Facts

Related News